NuLife to Present at Source Capital Group Disruptive Growth & Healthcare Conference

SAN CLEMENTE, CA --(Marketwired - January 25, 2017) - NuLife Sciences NULF through the Company's wholly-owned subsidiary, NuLife BioMed, Inc. today announced that management will present at the Source Capital Group 2nd Annual Disruptive Growth & Healthcare Conference being held February 15th and 16th in New York.

NuLife management will host one-on-one meetings throughout the day and is scheduled to present as follows:

Source Capital Group 2nd Annual Disruptive Growth & Healthcare Conference
Presentation: Wednesday, Feb 15 at 1:45-2:10 PM
Location: Convene, 730 Third Avenue, New York City, Track 1 - Tribeca

About NuLife Sciences

NuLife Sciences NULF is a biomedical company focused on advancing human organ transplant technology and medical research. NuLife has a patent protected unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal experiments on its pathway to commercialization.

Safe Harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.


FOR FURTHER INFORMATION PLEASE CONTACT:

Contact
Investor Relations
Ted Haberfield
MZ Group | President - MZ North America
Direct: 760-755-2716
Mobile: 858-204-5055
thaberfield@mzgroup.us
www.mzgroup.us